- Facing pharmacy trends for the remainder of the year
- FDA approves easy-to-use injectable methotrexate for RA, psoriasis, juvenile arthritis
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Campaign seeks to raise children's arthritis awareness
- Senate passes Drug Quality and Security Act
EAST HANOVER, N.J. — The Food and Drug Administration has approved a biotech drug made by Novartis for treating a form of arthritis that affects children, the Swiss drug maker said Friday.
Novartis announced the approval of Ilaris (canakinumab) for active systemic juvenile idiopathic arthritis in patients ages 2 years and older. The company said the drug was the first once-per-month drug for injection under the skin to be approved for SJIA. The disease is a rare and disabling form of arthritis characterized by spiking fever, rash and arthritis that can affect children as young as 2 years and continue into adulthood, according to studies. The drug is also approved for treating rare, lifelong and debilitating genetic disorders known as cryopyrin-associated periodic syndromes.
"In the United States, this approval marks the second Ilaris indication for patients living with rare, autoinflammatory conditions," Novartis Pharmaceuticals global head of development Timothy Wright said.